Andy

HANOVER, MD, Jan. 27, 2025 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced the pricing of its “reasonable best efforts” public offering with participation from the Company’s Chief Executive Officer, certain board members, and existing institutional investors of the Company, along with a healthcare focused institutional investor, consisting of 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 8,050,672 shares of common stock (or pre-funded warrants in lieu thereof) and Series B warrants to purchase up to 4,025,336 shares of common stock at a combined purchase price per share (and accompanying warrants) of $0.615 for the institutional investors and $0.7975 for the Company’s Chief Executive Officer and certain board members.

COLUMBIA, Md., (January 27, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $100,000 investment in ReBokeh through the Pre-Seed Builder Fund, a key program under the Social Impact Funds. This initiative provides early-stage businesses with access to funding and resources designed to support their growth and success.

“Having TEDCO in our corner has been incredibly valuable for ReBokeh,” said Rebecca Rosenberg, CEO of ReBokeh. “As a company that planted its roots in Baltimore, we’re both excited and immensely proud to continue being a part of the growing startup scene that calls Maryland home.”

BALTIMORE, Jan. 24, 2025 /PRNewswire/ — In two separate procedures, MedStar Health cardiac experts at MedStar Union Memorial Hospital reached new heights in cardiovascular care when they performed the state’s and the system’s first transcatheter tricuspid valve replacements (TTVR) using a recently FDA-approved valve, to treat life-threatening tricuspid regurgitation. On Jan. 7th, the male and female patients, both in their 80’s, received the revolutionary valves delivered via a catheter, foregoing the need for conventional open-heart surgery.

FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA trial for Descartes-08, its lead mRNA cell therapy candidate, in myasthenia gravis (MG). The SPA agreement indicates that the FDA has determined that the proposed trial design is acceptable to support a future Biologics License Application for Descartes-08 in MG, subject to the ultimate outcome of the trial.

COLUMBIA, Md., Jan. 24, 2025 /PRNewswire/ — TEDCO, Maryland’s economic engine for technology companies, announced nine awardees for the inaugural Maryland Student Venture Showcase and Pava LaPere Innovation Awards. The awards, funded by the State of Maryland through the Pava LaPere Legacy of Innovation Act of 2024, recognize and support outstanding student entrepreneurs from colleges and universities in the Baltimore–Towson–Columbia metropolitan statistical area.

“The Maryland Student Venture Showcase and Pava LaPere Innovation Awards are a testament to the incredible talent and innovation coming out of Maryland’s colleges and universities,” said Troy LeMaile-Stovall, TEDCO CEO. “We are excited to support these outstanding student entrepreneurs as they work to grow successful businesses.”

The 43rd Annual J.P. Morgan Healthcare Conference, held from January 13–16, 2025, in San Francisco, once again brought together industry leaders, investors, and innovators from around the globe. As the largest healthcare investment symposium, the event offered a platform to discuss breakthroughs in cancer, pain management, neurodegenerative diseases, artificial intelligence (AI) in drug development, and strategies for mergers and acquisitions (M&A).

Several of BioHealth Innovation’s (BHI) Entrepreneurs-in-Residence (EIRs) attended, sharing insights and observations from this pivotal event.

Emergent BioSolutions (Gaithersburg, US) has purchased US and Canadian rights to Kloxxado, adding to its opioid overdose treatment portfolio, which includes Narcan. The growing US opioid epidemic (including synthetic fentanyl) and its treatments will provide future growth drivers for Emergent, said Joe Papa, president and CEO of Emergent, at this year’s J.P. Morgan 43rd Annual Healthcare Conference on 15 January.

Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, then turning it around and ultimately transforming the company,” Papa told the conference. “It’s a multiyear process.”

COLUMBIA, Md., (January 24, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $250,000 Builder Fund investment in Nostopharma, a musculoskeletal therapeutic platform company focused on treating complications of trauma, orthopedic surgery and rare diseases musculoskeletal sequalae. TEDCO’s Builder Fund operates under the umbrella of Social Impact Funds and not only provides companies with investment funds but also offers various resources, including executive support, mentorship and assorted networking opportunities.

ROCKVILLE, Md. and SUZHOU, China, Jan. 23, 2025 (GLOBE NEWSWIRE) — Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the pricing of its U.S. initial public offering of 7,325,000 American depositary shares (“ADSs”), at a public offering price of $17.25 per ADS, before underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Ascentage Pharma, are expected to be approximately $126.4 million. In addition, Ascentage Pharma has granted the underwriters a 30-day option to purchase up to an additional 1,098,750 ADSs at the initial public offering price, less underwriting discounts and commissions. The ADSs are expected to begin trading on the Nasdaq Global Market on January 24, 2025, under the ticker “AAPGV” on a “when-issued” basis, and on January 27, 2025, under the ticker symbol “AAPG” for “regular-way” trading. The offering is expected to close on January 28, 2025, subject to customary closing conditions.